ReviewEndocrine2013
The unrelenting fall of the pharmacological treatment of obesity.
Review in Endocrine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Appetite-Suppressing and Satiety-Increasing Bioactive Phytochemicals: A Systematic Review.Nutrients · 2019Pooled it
- Obesity treatment by very low-calorie-ketogenic diet at two years: reduction in visceral fat and on the burden of disease.Endocrine · 2016Trial
- Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the treatment of obesity.Endocrine · 2014Trial
- Increasing adipocyte number and reducing adipocyte size: the role of retinoids in adipose tissue development and metabolism.Critical reviews in food science and nutrition · 2024Review
- A cardiac amino-terminal GRK2 peptide inhibits insulin resistance yet enhances maladaptive cardiovascular and brown adipose tissue remodeling in females during diet-induced obesity.Journal of molecular and cellular cardiology · 2023Review
- Structural analysis of the dual agonism at GLP-1R and GCGR.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- The best drug supplement for obesity treatment: a systematic review and network meta-analysis.Diabetology & metabolic syndrome · 2021Article
- Role of central neurotensin in regulating feeding: Implications for the development and treatment of body weight disorders.Biochimica et biophysica acta. Molecular basis of disease · 2018Review
- Pharmacological inhibition of adipose triglyceride lipase corrects high-fat diet-induced insulin resistance and hepatosteatosis in mice.Nature communications · 2017Article
- Can Brown Fat Win the Battle Against White Fat?Journal of cellular physiology · 2015Review
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.Nature medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nowadays pharmacological therapy to limit obesity has reached a critical stage: not only have Authorities limited the use of antiobesity drugs due to their proven inefficacy and dangerous side effects, but bariatric surgery has delivered better results. At present, when the number of obese subjects is growing exponentially worldwide and more and more pathological mechanisms inducing fat accumulation have been discovered, no drugs are available to help patients and physicians to limit one the most dreadful causes of death. Following the failures of promising drugs as sibutramine and rimonabant, many companies stopped to invest in the field of obesity pharmacotherapy. At the same time, leading Authorities have started to require more solid evidence before providing authorization for these drugs to enter the market. This review aims at revising the failed promises of antiobesity drugs and describing the few potential future candidates in order to shed some light in the still uncertain field of antiobesity drugs. It also provides a critical contribution to the ongoing debate among scientists, clinicians, patients and Authorities on the possibility to treat obesity with pharmacological drugs.
Indexed as
Identifiers
23677499What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.